<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Constitutively activated STAT3 and STAT5 are expressed in a wide variety of human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including solid and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematopoietic cancers</z:e> and often correlate with a poor prognosis and resistance to multiple therapies </plain></SENT>
<SENT sid="1" pm="."><plain>Given the well established role of STAT3 in <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, inhibition of Janus-activated kinase 2 (JAK2) activity might represent an attractive therapeutic approach </plain></SENT>
<SENT sid="2" pm="."><plain>Using a mouse model of <z:hpo ids='HP_0002583'>colitis</z:hpo>-induced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, we show that a novel, orally active, selective JAK2 inhibitor, CEP-33779, induced regression of established <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e>, <z:mp ids='MP_0005602'>reduced angiogenesis</z:mp>, and reduced proliferation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Histopathologic analysis confirmed reduced incidence of histologic-grade <z:hpo ids='HP_0002664'>neoplasia</z:hpo> by CEP-33779 </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0010537'>Tumor regression</z:mp> correlated with inhibition of STAT3 and NF-κB (RelA/p65) activation in a CEP-33779 dose-dependent manner </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the expression of proinflammatory, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-promoting cytokines interleukin (IL)-6 and IL-1β was strongly reduced upon JAK2 inhibition </plain></SENT>
<SENT sid="6" pm="."><plain>The ability of CEP-33779 to suppress growth of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> by inhibiting the IL-6/JAK2/STAT3 signaling suggests a potential therapeutic utility of JAK2 inhibitors in <z:e sem="disease" ids="C0260037" disease_type="Neoplastic Process" abbrv="">multiple tumors</z:e> types, particularly those with a strong inflammatory component </plain></SENT>
</text></document>